NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -13.46 against a street estimate of 4.20 — a miss of 420.5%.
with an average price target of ₹1,338.67.
| Document | Date |
|---|---|
| Q1 FY27 earnings call STRIDES PHARMA SCIENCE LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue (Topline): ₹1,263.6 crore, up 13% year-on-year • Gross Margin: 60.9%, up | 2026-08-03 |
| Quarterly results · Q1 FY27 | 2026-07-24 |
| Annual report FY2026 STRIDES PHARMA SCIENCE LIMITED – INVESTOR SUMMARY --- HEADLINE NUMBERS • Final Dividend: Rs. 5 per equity share (face value Rs. 10) for FY 2025-26 | 2026-07-21 |
| Q4 FY26 earnings call STRIDES PHARMA SCIENCE LIMITED – Q4 & FY26 SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 48,587 million (INR 48 billion), growth of 6.4% YoY • FY26 E | 2026-05-21 |
| Investor presentation · Q4 FY26 STRIDES PHARMA SCIENCE LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Revenue: ₹48,587m, up 6.4% YoY • FY26 Gross Margin: ₹29,000m (59.7% o | 2026-05-18 |
| Quarterly results · Q4 FY26 STRIDES PHARMA SCIENCE LIMITED – SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: Rs. 48,586.83 million (vs | 2026-05-18 |
| Q3 FY26 earnings call STRIDES PHARMA SCIENCE LIMITED Q3 FY'26 SUMMARY HEADLINE NUMBERS • Q3 FY'26 Revenue: Rs. 1,192 crores (~$134 million), up 3.6% year-on-year; 9-month | 2026-02-03 |
| Quarterly results · Q3 FY26 STRIDES PHARMA SCIENCE LIMITED – FINANCIAL SUMMARY Q3 & 9M Results ended December 31, 2025 --- HEADLINE NUMBERS • Q3 FY2025-26 Revenue from Operati | 2026-01-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Jul 31, 2026 | 2026-07-31 |
| Announcement | Date |
|---|---|
| Effective date announced for scheme of demerger involving two entities Strides Pharma Science Limited announced the effective date for its scheme of demerger. The company is splitting into separate entities: Strides will separate Arco Lab and Pivot Path into in | 2026-06-01 |
| Acquisition of multiple generic brands from Sandoz in Africa Strides Pharma has acquired multiple generic pharmaceutical brands from Sandoz in Africa. This strategic acquisition strengthens the company's presence in the African market, which is a key | 2026-03-17 |
| Acquisition of multiple generic brands from Sandoz Strides Pharma has acquired multiple generic pharmaceutical brands from Sandoz to strengthen its presence in the African market. This is a strategic expansion move in the generics segment, w | 2026-03-17 |
| Acquisition of multiple generic brands from Sandoz in Africa Strides Pharma Science Limited announced the acquisition of multiple generic pharmaceutical brands from Sandoz, strengthening its presence in the African market. This strategic move expands | 2026-03-17 |
| Wholly owned subsidiary acquires Neviton Softech Private Limited Strides Pharma Science Limited announced that its wholly-owned subsidiary, Arco Lab Private Limited, has acquired Neviton Softech Private Limited. However, the announcement lacks critical fi | 2026-02-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Strides Pharma Science Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.